Pharmacy Information

Pharmacy Updates

The purpose of CalOptima educational bulletins is to increase providers’ understanding of current treatment guidelines and recommendations on drugs, disease states, and medical conditions. Specific recommendations are made with each article on how to improve the quality of care for CalOptima members.

For more information about the CalOptima Pharmacy Program, please call Pharmacy Management at 1-714-246-8471.

May 2022: Pneumococcal Vaccine Update in Adults 

April 2022: Over-the-Counter (OTC) Products at No Cost 

March 2022: Safe Medication Disposal in the Community 

February 2022: Deprescribing Proton Pump Inhibitors in the Elderly 

January 2022: Opioid Prescribing Quality Measure Updates 

December 2021: Improving Medication Adherence for Chronic Conditions 

November 2021: Medi-Cal Pharmacy Benefit Carve Out (Medi-Cal Rx) 

October 2021: Annual Flu Vaccine Update 

September 2021: Statin Therapy for Patients with Diabetes 

August 2021: Deprescribing Benzodiazepines in Older Adults 

July 2021: Beta-Blocker Treatment Post-Myocardial Infarction 

June 2021: Diabetes Quality Measures 

May 2021: Medical Assistance with Smoking and Tobacco Use Cessation 

Contact Us
  • If you have questions, you can contact the CalOptima Pharmacy Management department Monday through Friday from 8 a.m. to 4 p.m. at 1-714-246-8471.
Residency Program
  • The CalOptima PGY-1 Managed Care Pharmacy Residency program provides residents with a broad overview of managed care pharmacy practice at a county organized health system (COHS).

    Download the brochure
Plan Profile Sheets
Pharmacy Benefit Manager is MedImpact
  • MedImpact administers CalOptima’s pharmacy program. It provides claims processing, pharmacy network management, prior authorization processing and drug utilization management services.

Download the free Adobe Reader.

Materials available on this website in PDF format may require the free Adobe Reader to view. To download Adobe Reader for free from the Adobe website, click here.